A Study of LY2181308 Sodium in Patients With Relapsed or Refractory Acute Myeloid Leukemia
Status:
Completed
Trial end date:
2010-01-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to understand the safety profile of LY2181308 sodium
administered in combination with idarubicin and cytarabine to patients with relapsed or
refractory acute myeloid leukemia (AML).